Trial Profile
A Phase I study to evaluate the pharmacokinetics of the single- and multiple- ascending doses of Apatinib Mesylate with or without food in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jun 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Pharmacokinetics
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record